FDA Warning Letter: Purolea Cosmetics Lab (Drugs)
FDA cites Purolea Cosmetics Lab for insects and filth in its plant and for untested homeopathic drug products.
What changed & why it matters
MedSpaRadar recorded an FDA Warning Letter at the federal level, dated April 2, 2026, in the Multi-topic category.
An FDA Warning Letter is a formal, public notice that a firm's conduct violated federal law. For a med spa it is a supplier-and-marketing signal: it names conduct the FDA considers unlawful, from compounding practices to the health claims a practice might echo.
- Type
- FDA Warning Letter
- Jurisdiction
- Federal
- Category
- Multi-topic
- Recorded
- April 2, 2026
What this means for your practice — the step to take, the deadline to calendar or the supplier detail to check, where the change calls for one — is in the member "what to do" below. This page is the free record of what changed and why it matters.
What to do
Free weekly Brief
Get the changes that matter in plain English, every week — and be alerted when the rules move. No charge.
Members get a specific “what to do” wherever a change calls for one — in one daily email, for your states. See one unlocked → · Pricing →
FDA Warning Letter · primary source ↗
Related alerts
- FDA Warning Letter: Active Cosmetics Manufacturing Inc (Drugs)
- FDA Warning Letter: Spa De Soleil, Inc. (Drugs)
- FDA Warning Letter: Foshan Miwei Cosmetics Co., Ltd. (Drugs)
- IN SB0282: Compounding drugs; registration of medical spas.
- FDA Warning Letter: ketaminelab.org (Drugs)
- FDA Warning Letter: Herbal Dermals LLC Fz (Drugs)
MedSpaRadar is regulatory monitoring and reference: it summarizes public laws, regulations and agency actions and links each to its source. It is not legal, medical, or compliance advice, and using it creates no attorney-client relationship. A summary can lag its source or leave out detail, and monitoring itself can be interrupted — so an absence of alerts means nothing reached you, not that nothing happened. Read the cited source, check its effective date, and confirm any change to your operations or clinical practice with qualified health-law counsel and your medical director.